In line of ABBV Upad P2b 32 w AD update,
finance.yahoo.com
and REGN decision to expand US manufacturing capacity by $800 M investment and Panorama sBLA file,
finance.yahoo.com ,
INCY topical Rux cream in mild/moderate AD,
finance.yahoo.com other pipeline/news from Roche,...
It is a good time to evaluate Eylea marketing prospect for years 19/20!
E continue to hold (and expand further) dominance in branded anti-VEGF market (70% US and ~60% ex-US), projecting total E US sale of $4.24B (18), $4.75B (19), and $5.32B (20), with ex-US E sale of $2.70B (18), $3.13B (19), and $3.57B (20).....give 2020 E sale of ~ $8.89B.
Counting ~5% in COGS, ~20% in S&G expense, and 15% taxes, leave net profit of $5.33B. So, IF company X want to recapture Eylea acquisition price in 7 years, give current Eylea value of $37.3 B.
At current $42B MC, REGN EV of pipeline and business is $5B. IF someone think that this is too-much, I will land him my REGN shares to short!
Cheers! |
